CN113474045A - Pd-l1特异性的双环肽配体 - Google Patents

Pd-l1特异性的双环肽配体 Download PDF

Info

Publication number
CN113474045A
CN113474045A CN201980081015.6A CN201980081015A CN113474045A CN 113474045 A CN113474045 A CN 113474045A CN 201980081015 A CN201980081015 A CN 201980081015A CN 113474045 A CN113474045 A CN 113474045A
Authority
CN
China
Prior art keywords
seq
bcy
hereinafter referred
iii
sdk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980081015.6A
Other languages
English (en)
Chinese (zh)
Inventor
L·陈
J·库克
K·麦克唐纳
G·马德
K·范里茨霍滕
P·乌帕德亚雅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BicycleTx Ltd
Original Assignee
BicycleTx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1820956.9A external-priority patent/GB201820956D0/en
Priority claimed from GBGB1904621.8A external-priority patent/GB201904621D0/en
Priority claimed from GBGB1905631.6A external-priority patent/GB201905631D0/en
Application filed by BicycleTx Ltd filed Critical BicycleTx Ltd
Publication of CN113474045A publication Critical patent/CN113474045A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201980081015.6A 2018-12-21 2019-12-23 Pd-l1特异性的双环肽配体 Pending CN113474045A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB1820956.9A GB201820956D0 (en) 2018-12-21 2018-12-21 Bicyclic peptide ligands specific for pd-l1
GB1820956.9 2018-12-21
GBGB1904621.8A GB201904621D0 (en) 2019-04-02 2019-04-02 Bicyclic peptide ligands specific for PD-L1
GB1904621.8 2019-04-02
GB1905631.6 2019-04-23
GBGB1905631.6A GB201905631D0 (en) 2019-04-23 2019-04-23 Bicyclic peptide ligands specific for pd-l1
US201962910113P 2019-10-03 2019-10-03
US62/910,113 2019-10-03
PCT/GB2019/053679 WO2020128526A1 (en) 2018-12-21 2019-12-23 Bicyclic peptide ligands specific for pd-l1

Publications (1)

Publication Number Publication Date
CN113474045A true CN113474045A (zh) 2021-10-01

Family

ID=71100278

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980081015.6A Pending CN113474045A (zh) 2018-12-21 2019-12-23 Pd-l1特异性的双环肽配体

Country Status (5)

Country Link
US (1) US12492224B2 (enExample)
EP (1) EP3897849A1 (enExample)
JP (2) JP2022514618A (enExample)
CN (1) CN113474045A (enExample)
WO (1) WO2020128526A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2708459C2 (ru) 2014-10-29 2019-12-09 БайсиклРД Лимитед Бициклические пептидные лиганды, специфичные для мт1-ммр
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
CA3137095A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
EP4464721B1 (en) 2019-10-03 2025-06-11 BicycleTX Limited Heterotandem bicyclic peptide complexes
CN111961117B (zh) * 2020-08-19 2022-03-11 中山大学 一种环肽化合物及其应用
TW202233664A (zh) * 2020-11-13 2022-09-01 英商拜西可泰克斯有限公司 特用於運鐵蛋白受體之雙環胜肽配位基
CA3195317A1 (en) * 2020-11-30 2022-06-02 Fred Hutchinson Cancer Center Pd-l1 binding peptides and peptide complexes and methods of use thereof
CA3217018A1 (en) * 2021-01-08 2022-07-14 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
WO2022148975A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
US20250121076A1 (en) * 2021-08-17 2025-04-17 Medshine Discovery Inc. Polypeptide drug conjugate having novel structure and application thereof
WO2024261490A1 (en) 2023-06-23 2024-12-26 Bicycletx Limited Bicyclic peptide ligands specific for nk cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015188934A1 (en) * 2014-06-10 2015-12-17 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
CN107810190A (zh) * 2015-04-28 2018-03-16 洛桑联邦政府综合工科学校（Epfl) 酶活化因子XII (FXIIa)的新型抑制剂
CN107849142A (zh) * 2015-05-15 2018-03-27 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
WO2018222987A1 (en) * 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs

Family Cites Families (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2642514A (en) 1946-08-10 1953-06-16 American Cyanamid Co Ion exchange process with magnetic ion exchange resins
GB1239978A (en) 1968-07-15 1971-07-21 Permutt Company Ltd Ion-exchange processes
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
JP2001505194A (ja) 1996-11-05 2001-04-17 ブリストル―マイヤーズ・スクイブ・カンパニー 分枝ペプチド・リンカー
US6410275B1 (en) 1997-05-02 2002-06-25 Biomerieux, Inc. Disposable test devices for performing nucleic acid amplification reactions
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
JP4630459B2 (ja) 1998-09-24 2011-02-09 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 水溶性発光量子ドットおよびその生体分子コンジュゲート
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
UA72290C2 (uk) 1999-12-10 2005-02-15 Пфайзер Продактс Інк. СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ)
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
HUE036891T2 (hu) 2002-02-21 2018-08-28 Inst Virology MN/CA IX-deficiens egerekbõl létrehozott MN/CA IX-specifikus monoklonális ellenanyagok és alkalmazási eljárások
EP2055310B1 (en) 2002-08-14 2015-12-16 Silence Therapeutics GmbH Protein kinase N beta for the diagnosis and the treatment of late stage tumor
EP1569956B1 (en) 2002-12-12 2014-02-26 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
BRPI0409063A (pt) 2003-04-03 2006-03-28 Semafore Pharmaceuticals Inc pró medicamentos de inibidor de pi-3 cinase
BRPI0410870A (pt) 2003-05-30 2006-07-04 Gemin X Biotechnologies Inc compostos trieterocìclicos, composições, e métodos para tratar cáncer ou doenças virais
CN100577680C (zh) 2003-07-03 2010-01-06 宾夕法尼亚大学理事会 对Syk激酶表达的抑制
EP1720907B1 (en) 2004-02-06 2015-04-08 MorphoSys AG Anti-cd38 human antibodies and uses therefor
US7151047B2 (en) 2004-04-28 2006-12-19 Warren Chan Stable, water-soluble quantum dot, method of preparation and conjugates thereof
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP2161275A1 (en) 2005-01-19 2010-03-10 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
EP1844337B1 (en) 2005-01-24 2013-07-03 Pepscan Systems B.V. Binding compounds, immunogenic compounds and peptidomimetics
EP1866328B1 (en) 2005-03-22 2011-01-12 Rohto Pharmaceutical Co., Ltd. Peptides which increase collagen or hyaluronic acid production
EP1866339B8 (en) 2005-03-25 2021-12-01 GITR, Inc. Gitr binding molecules and uses therefor
KR101533268B1 (ko) 2005-05-12 2015-07-03 애브비 바하마스 리미티드 아폽토시스 촉진제
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
WO2007030642A2 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
EP1931645B1 (en) 2005-10-07 2014-07-16 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
NZ592990A (en) 2005-11-01 2013-01-25 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
DK3184526T3 (en) 2005-12-13 2019-01-14 Incyte Holdings Corp PYRROLO [2,3-D] PYRIMIDINE DERIVATIVES AS A JANUS-KINASE INHIBITOR
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007093836A1 (en) 2006-02-13 2007-08-23 Cellectis Meganuclease variants cleaving a dna target sequence from a xp gene and uses thereof
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
AU2007294685B2 (en) 2006-09-15 2012-06-07 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
PT2201840E (pt) 2006-09-22 2012-02-14 Pharmacyclics Inc Inibidores da tirosina quinase de bruton
CN101232326B (zh) 2007-01-22 2012-01-11 中兴通讯股份有限公司 用于无源光网络系统的动态带宽分配装置及其实现方法
CN101861313B (zh) 2007-03-12 2014-06-04 Ym生物科学澳大利亚私人有限公司 苯基氨基嘧啶化合物及其用途
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
WO2008134761A2 (en) 2007-04-30 2008-11-06 Intezyne Technologies, Inc. Modification of biological targeting groups for the treatment of cancer
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
JP2010530437A (ja) 2007-06-18 2010-09-09 メディミューン，エルエルシー ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
WO2009097397A2 (en) 2008-01-30 2009-08-06 Dyax Corp. Metalloproteinase binding proteins
CN101497878B (zh) 2008-01-30 2012-11-07 房学迅 特异性高效亲和膜ⅰ型基质金属蛋白酶(mt1-mmp)的多肽、蛋白及其应用
DK2257624T5 (da) 2008-02-05 2012-09-10 Medical Res Council Fremgangsmåder og sammensætninger
DK2257309T3 (da) 2008-02-27 2020-01-20 Yeda Res And Development Company Ltd Rgd-(bakterie)chlorophyl-konjugater til anvendelse ved diagnose af tumorer, der omfatter nekrotiske domæner
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
FR2932189A1 (fr) 2008-06-10 2009-12-11 Commissariat Energie Atomique Biopuces pour la detection de l'activite enzymatique d'une enzyme protease
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8834926B2 (en) 2008-08-08 2014-09-16 University Of Delaware Macromolecular diffusion and release from self-assembled β-hairpin peptide hydrogels
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
EP2433322A4 (en) 2009-05-19 2015-11-04 East Penn Mfg Co COMPOSITE CURRENT COLLECTOR AND RELATED METHODS
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
CN102574924A (zh) 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
CA2777242A1 (en) * 2009-10-14 2011-04-21 Merrimack Pharmaceuticals, Inc. Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
NZ599774A (en) 2009-11-23 2014-11-28 Palatin Technologies Inc Melanocortin-1 receptor-specific cyclic peptides
PT2949670T (pt) 2009-12-10 2019-05-20 Hoffmann La Roche Anticorpos que se ligam preferencialmente ao domínio extracelular 4 do csf1r e respetiva utilização
US9073974B2 (en) 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
JP2013518807A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 多重特異性ペプチド
JP2013518558A (ja) * 2010-02-04 2013-05-23 メディカル リサーチ カウンシル 構造化されたペプチドプロセシング
NZ705128A (en) 2010-03-04 2015-04-24 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
WO2011107553A1 (en) 2010-03-05 2011-09-09 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
CN107011438B (zh) 2010-05-04 2020-11-20 戊瑞治疗有限公司 结合csf1r的抗体
SG10201912092VA (en) 2010-09-09 2020-02-27 Pfizer 4-1bb binding molecules
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130072598A1 (en) 2011-03-18 2013-03-21 Board Of Regents Of The University Of Nebraska Thermoplastics from Distillers Dried Grains and Feathers
NO2694640T3 (enExample) 2011-04-15 2018-03-17
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
CN103906865B (zh) 2011-10-07 2017-12-08 拜斯科医疗有限公司 结构化多肽特异性的调控
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AU2012374617B2 (en) 2012-05-11 2015-09-17 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
SG10201906328RA (en) 2012-08-31 2019-08-27 Five Prime Therapeutics Inc Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
SG10201702387YA (en) 2012-09-24 2017-04-27 Medimmune Ltd Cell lines
WO2014063012A1 (en) 2012-10-19 2014-04-24 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
CA2902432A1 (en) 2013-03-12 2014-10-09 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
US20140274759A1 (en) 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
JP6197865B2 (ja) 2013-03-15 2017-09-20 日本ゼオン株式会社 中空重合体粒子の水性分散液およびその製造方法
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
TW201536311A (zh) 2013-07-22 2015-10-01 Kineta One Llc 基於毒素之治療性肽的眼科用途及其醫藥組合物
US20150087810A1 (en) 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
CN105683211B (zh) 2013-10-28 2020-10-20 拜斯科阿迪有限公司 新型多肽
EA031804B1 (ru) 2014-02-03 2019-02-28 Вайтаи Фармасьютиклз, Инк. Дигидропирролопиридиновые ингибиторы ror-гамма
US20170165334A1 (en) * 2015-12-11 2017-06-15 Tianxin Wang Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification
RU2744836C2 (ru) 2014-05-08 2021-03-16 Новодиакс, Инк. Прямой иммуногистохимический анализ
HRP20191254T1 (hr) 2014-05-21 2019-10-18 Entrada Therapeutics, Inc. Peptidi koji prodiru u stanice i postupci za njihovu proizvodnju i uporabu
GB201416960D0 (en) 2014-09-25 2014-11-12 Antikor Biopharma Ltd Biological materials and uses thereof
JP6917887B2 (ja) 2014-09-30 2021-08-11 ポリフォー・アクチェンゲゼルシャフトＰｏｌｙｐｈｏｒ Ａｇ ベータ−ヘアピンペプチド模倣体
US10829558B2 (en) 2014-10-24 2020-11-10 Research Corporation Technologies, Inc. Small antibody-like polypeptides that bind to EPHA2 receptor
RU2708459C2 (ru) 2014-10-29 2019-12-09 БайсиклРД Лимитед Бициклические пептидные лиганды, специфичные для мт1-ммр
US10011657B2 (en) 2014-10-31 2018-07-03 Abbvie Biotherapeutics Inc. Anti-CS1 antibodies and antibody drug conjugates
KR20170125799A (ko) 2014-12-04 2017-11-15 셀진 코포레이션 생체분자 컨쥬게이트
IL237525A (en) 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
WO2016171272A1 (ja) 2015-04-22 2016-10-27 三井化学株式会社 関節用サポーター部を備える衣類、及び膝用サポーター
WO2016171242A1 (ja) 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
JP7366518B2 (ja) 2015-05-06 2023-10-23 ヤンセン バイオテツク，インコーポレーテツド 前立腺特異的膜抗原結合フィブロネクチンｉｉｉ型ドメイン
EP3115066A1 (en) 2015-07-07 2017-01-11 Technische Universität München Novel psma-specific binding proteins
US9963495B2 (en) 2015-10-27 2018-05-08 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor and prostate specific membrane antigen
EP3181146A1 (en) 2015-12-16 2017-06-21 Ruprecht-Karls-Universität Heidelberg Cyclic ntcp-targeting peptides and their uses as entry inhibitors
GB201600911D0 (en) 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
WO2017160879A1 (en) 2016-03-15 2017-09-21 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
WO2017161069A1 (en) 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc Nanoliposomal targeting of ephrin receptor a2 (epha2) and related diagnosticss
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
PH12018501777B1 (en) 2016-04-20 2022-08-10 Hangzhou Dac Biotech Co Ltd Derivatives of amanita toxins and their conjugation to a cell binding molecule
WO2017182672A1 (en) 2016-04-22 2017-10-26 Alligator Bioscience Ab Novel bispecific polypeptides against cd137
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
CA3025345A1 (en) 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
WO2018096365A1 (en) 2016-11-27 2018-05-31 Bicyclerd Limited Methods for treating cancer
CN110603261A (zh) 2016-12-23 2019-12-20 拜斯科阿迪有限公司 具有新型键结构的肽衍生物
JP7387440B2 (ja) 2016-12-23 2023-11-28 バイスクルテクス・リミテッド Ｍｔ１－ｍｍｐに結合するためのペプチドリガンド
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
WO2018133873A1 (zh) * 2017-01-23 2018-07-26 苏州康宁杰瑞生物科技有限公司 Pd-l1结合多肽或化合物
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB2562721A (en) * 2017-05-16 2018-11-28 Fastbase Solutions Ltd Kits, methods and their uses for detecting cell-cell interactions in a sample
US10899798B2 (en) 2017-06-26 2021-01-26 Bicyclerd Limited Bicyclic peptide ligands with detectable moieties and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
EP3668887A1 (en) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
EP3668550A1 (en) 2017-08-14 2020-06-24 Bicyclerd Limited Bicyclic peptide ligand prr-a conjugates and uses thereof
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
CN111601619A (zh) 2017-11-07 2020-08-28 里珍纳龙药品有限公司 用于抗体药物偶联物的亲水性连接体
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
US11572370B2 (en) 2018-01-08 2023-02-07 Biohaven Therapeutics Ltd. CD16A binding agents and uses thereof
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
SG11202009773VA (en) 2018-04-04 2020-10-29 Bicycletx Ltd Heterotandem bicyclic peptide complexes
TW202003580A (zh) 2018-05-21 2020-01-16 美商坎伯斯治療有限責任公司 用於增強nk細胞對標靶細胞之殺死之組合物及方法
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201810327D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to IL-17
GB201810325D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to PSMA
GB201810320D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to CD38
GB201810329D0 (en) 2018-06-22 2018-08-08 Bicycletx Ltd Peptide ligands for binding to integrin avB3
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
US20200129630A1 (en) 2018-10-30 2020-04-30 Bicyclerd Limited Methods for treating cancer
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
SG11202106081YA (en) 2018-12-13 2021-07-29 Bicycletx Ltd Bicyclic peptide ligands specific for mt1-mmp
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
CN119896730A (zh) 2018-12-17 2025-04-29 雷维托普有限公司 双免疫细胞衔接物
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
EP3897850A1 (en) 2018-12-21 2021-10-27 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
US10882987B2 (en) 2019-01-09 2021-01-05 Nova Chemicals (International) S.A. Ethylene interpolymer products having intermediate branching
GB201900525D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for caix
GB201900530D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for CD38
GB201900528D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for integrin AVB3
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
GB201900527D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for integrin avb3
GB201900526D0 (en) 2019-01-15 2019-03-06 Bicyclerd Ltd Bicyclic peptide ligands specific for caix
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
US20220135614A1 (en) 2019-03-04 2022-05-05 Bicyclerd Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
EP3946462A1 (en) 2019-04-02 2022-02-09 BicycleTX Limited Bicycle toxin conjugates and uses thereof
CA3137095A1 (en) 2019-05-09 2020-11-12 Bicycletx Limited Bicyclic peptide ligands specific for ox40
TWI869398B (zh) 2019-05-10 2025-01-11 英商拜西克爾德有限公司 治療癌症之方法
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
WO2021028686A1 (en) 2019-08-13 2021-02-18 Bicycletx Limited Modified multimeric bicyclic peptide ligands
GB201912320D0 (en) 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
EP4464721B1 (en) 2019-10-03 2025-06-11 BicycleTX Limited Heterotandem bicyclic peptide complexes
GB201914872D0 (en) 2019-10-15 2019-11-27 Bicycletx Ltd Bicyclic peptide ligand drug conjugates
US20220387611A1 (en) 2019-10-16 2022-12-08 Bicyclerd Limited Methods for treating cancer
US20230025916A1 (en) 2019-11-27 2023-01-26 Bicycle TX Limited BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF
IT202000001231A1 (it) 2020-01-22 2021-07-22 Celery S R L Nuovi ceppi di batteri lattici, composizione alimentare che li comprende, preparazione di tale composizione
GB202002705D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Anti-infective bicyclic peptide conjugates
GB202002706D0 (en) 2020-02-26 2020-04-08 Bicycletx Ltd Pbp3 binding bicyclic peptide ligands
KR20230037502A (ko) 2020-05-20 2023-03-16 바이사이클티엑스 리미티드 넥틴-4에 특이적인 바이사이클릭 펩티드 리간드 및 이의 용도
MX2022015419A (es) 2020-06-12 2023-03-17 Bicycletx Ltd Tratamiento de enfermedades caracterizadas por la sobreexpresion del receptor hepatocelular productor de eritropoyetina a2 (epha2).
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
KR20230074721A (ko) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
WO2022148975A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Heterotandem bicyclic peptide complexes
EP4274837A1 (en) 2021-01-08 2023-11-15 BicycleTx Limited Anti-infective bicyclic peptide ligands
CA3217018A1 (en) 2021-01-08 2022-07-14 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
AU2022340959A1 (en) 2021-09-03 2024-03-07 Bicycletx Limited Synthesis of bicycle toxin conjugates, and intermediates thereof
JP2024543505A (ja) 2021-11-16 2024-11-21 バイスクルテクス・リミテッド 癌の治療方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015188934A1 (en) * 2014-06-10 2015-12-17 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
CN106794264A (zh) * 2014-06-10 2017-05-31 3B制药有限公司 包含神经降压肽受体配体的缀合物及其用途
CN107810190A (zh) * 2015-04-28 2018-03-16 洛桑联邦政府综合工科学校（Epfl) 酶活化因子XII (FXIIa)的新型抑制剂
CN107849142A (zh) * 2015-05-15 2018-03-27 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
WO2018222987A1 (en) * 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN: "Peptide Ligands Stabilized by Small Molecules", ANGEW CHEM INT ED ENGL, vol. 53, no. 6, pages 1602 - 1606, XP055356354, DOI: 10.1002/anie.201309459 *
SHABNAM SHAABANI: "A patent review on PD-1/PD-L1 antagonists: small molecules, peptides and macrocycles (2015–2018)", HHS PUBLIC ACCESS, vol. 28, no. 9, pages 665 - 678, XP055669361, DOI: 10.1080/13543776.2018.1512706 *

Also Published As

Publication number Publication date
JP2025020121A (ja) 2025-02-12
US20210101932A1 (en) 2021-04-08
JP2022514618A (ja) 2022-02-14
US12492224B2 (en) 2025-12-09
WO2020128526A1 (en) 2020-06-25
EP3897849A1 (en) 2021-10-27
US20220306689A9 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
CN113474045A (zh) Pd-l1特异性的双环肽配体
US11672868B2 (en) Bicyclic peptide ligands specific for MT1-MMP
CN111741771B (zh) 特异于epha2的双环肽配体
CN114555626B (zh) 异串联双环肽复合物
CN111183147B (zh) Cd137特异性的双环肽配体
CN113260420A (zh) Pd-l1特异性的双环肽配体
CN113518648B (zh) Mt1-mmp特异性的双环肽配体
CN114901317A (zh) 双环肽配体药物偶联物
CN113507960A (zh) Psma特异性的双环肽配体
CN113383007A (zh) Caix特异性的双环肽配体
CN113543813B (zh) Cd38特异性的双环肽配体
CN113439088A (zh) 整联蛋白αvβ3特异性的双环肽配体
CN113383074A (zh) Caix特异性的双环肽配体
CN113613728A (zh) 整联蛋白αvβ3特异性的双环肽配体
CN112585157A (zh) 用于结合整联蛋白αvβ3的肽配体
CN113474047A (zh) Mt1-mmp特异性的双环肽配体
CN113474046A (zh) Il-17特异性的双环肽配体
CN113507961A (zh) FAPα特异性的双环肽配体
CN114787177A (zh) Il-17特异性的双环肽配体
CN114867736A (zh) Il-17特异性的双环肽配体
CN114787176A (zh) Il-17特异性的双环肽配体
CN114829376A (zh) Il-17特异性的双环肽配体
RU2824959C2 (ru) Бициклические пептидные лиганды, специфичные для mt1-mmp
HK40058108A (en) Bicyclic peptide ligands specific for mt1-mmp
HK1243438B (en) Bicyclic peptide ligands specific for mt1-mmp

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination